Structural modeling of tissue-specific mitochondrial alanyl-tRNA synthetase (AARS2) defects predicts differential effects on aminoacylation

The accuracy of mitochondrial protein synthesis is dependent on the coordinated action of nuclear-encoded mitochondrial aminoacyl-tRNA synthetases (mtARSs) and the mitochondrial DNA-encoded tRNAs. The recent advances in whole-exome sequencing have revealed the importance of the mtARS proteins for mitochondrial pathophysiology since nearly every nuclear gene for mtARS (out of 19) is now recognized as a disease gene for mitochondrial disease. Typically, defects in each mtARS have been identified in one tissue-specific disease, most commonly affecting the brain, or in one syndrome. However, mutations in the AARS2 gene for mitochondrial alanyl-tRNA synthetase (mtAlaRS) have been reported both in patients with infantile-onset cardiomyopathy and in patients with childhood to adulthood-onset leukoencephalopathy. We present here an investigation of the effects of the described mutations on the structure of the synthetase, in an effort to understand the tissue-specific outcomes of the different mutations. The mtAlaRS differs from the other mtARSs because in addition to the aminoacylation domain, it has a conserved editing domain for deacylating tRNAs that have been mischarged with incorrect amino acids. We show that the cardiomyopathy phenotype results from a single allele, causing an amino acid change R592W in the editing domain of AARS2, whereas the leukodystrophy mutations are located in other domains of the synthetase. Nevertheless, our structural analysis predicts that all mutations reduce the aminoacylation activity of the synthetase, because all mtAlaRS domains contribute to tRNA binding for aminoacylation. According to our model, the cardiomyopathy mutations severely compromise aminoacylation whereas partial activity is retained by the mutation combinations found in the leukodystrophy patients. These predictions provide a hypothesis for the molecular basis of the distinct tissue-specific phenotypic outcomes.

[1]  Robert W. Taylor,et al.  Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy. , 2014, American journal of human genetics.

[2]  C. Elger,et al.  A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy , 2014, Neurology.

[3]  E. Holme,et al.  Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome , 2014, Molecular genetics & genomic medicine.

[4]  A. Palotie,et al.  Mitochondrial EFTs defects in juvenile-onset Leigh disease, ataxia, neuropathy, and optic atrophy , 2014, Neurology.

[5]  N. Larsson,et al.  Making proteins in the powerhouse. , 2014, Cell metabolism.

[6]  Beril Talim,et al.  Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. , 2014, JAMA.

[7]  S. Yokoyama,et al.  The selective tRNA aminoacylation mechanism based on a single G•U pair , 2014, Nature.

[8]  A. Vanderver,et al.  Novel (ovario) leukodystrophy related to AARS2 mutations , 2014, Neurology.

[9]  M. Minczuk,et al.  VARS2 and TARS2 Mutations in Patients with Mitochondrial Encephalomyopathies , 2014, Human mutation.

[10]  V. Tiranti,et al.  The Mitochondrial Aminoacyl tRNA Synthetases: Genes and Syndromes , 2014, International journal of cell biology.

[11]  Robert W. Taylor,et al.  ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy. , 2013, American journal of human genetics.

[12]  T. Walsh,et al.  Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome. , 2013, American journal of human genetics.

[13]  H. Tyynismaa,et al.  Mitochondrial aminoacyl-tRNA synthetases in human disease. , 2013, Molecular genetics and metabolism.

[14]  A. Paetau,et al.  Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy , 2013, Journal of Medical Genetics.

[15]  A. Paetau,et al.  Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. , 2012, Human molecular genetics.

[16]  J. Simpson,et al.  Mutations in mitochondrial histidyl tRNA synthetase (HARS2) is not associated with premature ovarian failure in a cohort of 69 patients , 2012 .

[17]  T. Meitinger,et al.  Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. , 2012, American journal of human genetics.

[18]  E. Bertini,et al.  Leukoencephalopathy with thalamus and brainstem involvement and high lactate 'LTBL' caused by EARS2 mutations. , 2012, Brain : a journal of neurology.

[19]  J. Nunnari,et al.  Mitochondria: In Sickness and in Health , 2012, Cell.

[20]  Jean-Pierre Bouchard,et al.  Mutations in the Mitochondrial Methionyl-tRNA Synthetase Cause a Neurodegenerative Phenotype in Flies and a Recessive Ataxia (ARSAL) in Humans , 2012, PLoS biology.

[21]  D. Jaffe,et al.  Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing , 2012, Science Translational Medicine.

[22]  V. Beneš,et al.  Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy , 2011, Human mutation.

[23]  A. Rötig.  Human diseases with impaired mitochondrial protein synthesis. , 2011, Biochimica et biophysica acta.

[24]  Matej Oresic,et al.  Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. , 2011, American journal of human genetics.

[25]  T. Walsh,et al.  Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome , 2011, Proceedings of the National Academy of Sciences.

[26]  R. Belostotsky,et al.  Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. , 2011, American journal of human genetics.

[27]  R. Giegé,et al.  Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome. , 2010, American journal of human genetics.

[28]  Xiang-Lei Yang,et al.  Paradox of mistranslation of serine for alanine caused by AlaRS recognition dilemma , 2009, Nature.

[29]  T. Katoh,et al.  Biogenesis of glutaminyl-mt tRNAGln in human mitochondria , 2009, Proceedings of the National Academy of Sciences.

[30]  Xiang-Lei Yang,et al.  The C-Ala Domain Brings Together Editing and Aminoacylation Functions on One tRNA , 2009, Science.

[31]  J. Gomori,et al.  Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. , 2007, American journal of human genetics.

[32]  R. Schiffmann,et al.  Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation , 2007, Nature Genetics.

[33]  M. Ibba,et al.  Loss of Editing Activity during the Evolution of Mitochondrial Phenylalanyl-tRNA Synthetase* , 2005, Journal of Biological Chemistry.

[34]  S. Kelley,et al.  An aminoacyl-tRNA synthetase with a defunct editing site. , 2005, Biochemistry.

[35]  Paul Schimmel,et al.  Elucidation of tRNA‐dependent editing by a class II tRNA synthetase and significance for cell viability , 2003, The EMBO journal.

[36]  O. Nureki,et al.  [Aminoacyl-tRNA synthetase]. , 1994, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[37]  Lyal B. Harris.  November , 1890, The Hospital.

[38]  C. Florentz,et al.  Pathogenic implications of human mitochondrial aminoacyl-tRNA synthetases. , 2014, Topics in current chemistry.

[39]  P. Stadler,et al.  Translation in Mammalian Mitochondria: Order and Disorder Linked to tRNAs and Aminoacyl-tRNA Synthetases , 2013 .